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Purpose: The use of surgery versus stomach-preserving
treatment for primary gastric lymphoma has caused contr-
oversy among doctors. This retrospective, single center study
aims to evaluate the efficacy and benefit of stomach-pre-
serving treatment against surgery for early stage diffuse
large B-cell lymphoma of stomach. Materials and Methods:
From August 1991 to January 2006, 43 cases of early-stage
diffuse large B-cell gastric lymphoma were reviewed.
Results: Eleven cases were treated with chemotherapy or
chemotherapy plus radiation (CT ± RT), 17 were treated with
surgery alone (OP), and 15 were treated with surgery plus
adjuvant chemotherapy (OP + CT). The complete remission
and response rates were 63.6% and 90.9% in those treated
with CT ± RT (7 complete responders, 3 partial responders,
1 non-responder), 100% and 100% in those treated with OP,
and 100% and 100% in those treated with OP + CT,
respectively. Five-year overall survival rates were 85.7%,
87.5%, and 100% in those treated by CT ± RT, OP, and OP
+ CT, respectively (p = 0.76). The five-year disease free
survival rates were 100%, 87.5% and 100% in those treated
by CT ± RT, OP, and OP + CT, respectively (p = 0.99).
There was no significant difference in overall survival and
disease free survival between modalities. Even though there
are no definite differences in the number of complications
between those treated by CT ± RT or OP, these facts reflect
little concern on complications after surgery. Conclusion: In
preventing morbidity arising from early or late complications
from surgery and promoting quality of life, chemotherapy
should be a primary consideration for early stage diffuse
large B-cell lymphoma of the stomach.
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INTRODUCTION
Gastric non-Hodgkin’s lymphoma accounts for
less than 15% of gastric malignancies and 2% of
lymphomas, and the stomach is the most common
site of extra-nodal involvement in non-Hodgkins’s
lymphoma.1-3 Radical surgery has been considered
essential for diagnosis and determination of disease
stage and for regional tumor control. MALT-type
lymphoma is strongly associated with Helicobacter
pylori infection, and eradication of H.pylori with
antibiotics has replaced radical surgery for the
initial treatment of MALT-type lymphoma.4 For
advanced disease, chemotherapy has been the first
line of treatment, while in localized disease
(stages IE, II1E, and II2E), treatment modalities
are controversial. Therefore, we undertook a study
to compare the results of treatment modalities in
early stage primary gastric diffuse large B-cell
lymphoma.
MATERIALS AND METHODS
Patients
We reviewed the records of 43 patients diagnosed
between 31 August 1991 and 28 October 2005
with localized gastric diffuse large B-cell
lymphoma who were treated at Yonsei Medical
Center. Based on Lewin et al,5 primary gastric
lymphoma was defined as disease confined to the
stomach or clearly predominant within the
stomach and with gastrointestinal symptoms. All
cases were histologically proven as diffuse large
B-cell lymphoma. Cases of MALT-type lymphoma
were excluded.
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Staging & response criteria
Staging procedures included physical exami-
nation, complete blood cell count with differential
count, blood chemistry, chest x-ray, upper gastro-
intestinal endoscopy with biopsy, and computed
tomography of the chest, abdomen, and pelvis.
Positron emission tomography was used on
recently diagnosed patients for staging evaluation.
Some patients with stage I cancer who received
surgical treatment did not undergo bone marrow
aspiration and biopsy. Stage was assessed using
the Musshoff modification of Ann Arbor system.
Stage IE disease was defined as disease confined
to stomach only. Stage IIE was defined as disease
extending into the abdomen with involvement of
local (perigastric) lymph nodes (IIE1) or even
distant (mesenteric, paraortic) lymph nodes (IIE2).
Response evaluation was defined according to
World Health Organization criteria. A complete
response or remission was defined as the complete
disappearance of all measurable lesions for at
least 4 weeks. A partial response or response was
defined as greater than or equal to a 50% reduction
in the size of all measurable lesions for at least 4
weeks with no appearance of new lesions. A
progressive disease was defined as at least a 25%
increase lesion size. Stable disease was defined as
a disease that met neither partial response nor
progressive disease criteria.
Statistical analysis
Overall survival was calculated using the date
of diagnosis to January 8, 2006 or death, whichever
occurred first. For those undergoing chemotherapy
or chemotherapy plus radiotherapy, disease-free
survival was calculated as the time from the
documented date of complete response to the first
relapse or last follow up date, whichever occurred
first. For those undergoing surgery or surgery
plus chemotherapy, disease-free survival was
calculated as the time from the date of surgery to
the date of relapse or the last follow up, whichever
came first. Survival rate was estimated by the
Kaplan-Meier method, and differences were
evaluated using the Log-rank test.
RESULTS
Patient characteristics
Patient characteristics and clinical features are
summarized in Table 1. There were 21 cases
(48.8%) of stage IE disease, 14 cases (32.6%) of
Table 1. Patient Characteristics
CT ± RT OP OP + CT Total
No. of cases (%) 11 (25) 17 (41) 15 (34) 43
Age, mean (yrs) 52.9 53.4 52.7 52.9
Range 41 - 71 17 - 74 36 - 72 17 - 74
Sex M 5 7 8 20
F 6 10 7 23
Stage IE 3 13 5 21
IIE1 4 3 7 14
IIE2 4 1 3 8
Total gastrectomy - 1 11 12
Subtotal gastrectomy - 16 4 20
B symptoms 1 1 0 2
CT ± RT, chemotherapy ± radiotherapy; RT, radiotherapy; OP, operation.
A patient who refused treatment was excluded.
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stage IIE1 disease, and 8 cases (18.6%) of stage
IIE2 disease. Two cases had B symptoms (4.7%).
Chemotherapy or chemotherapy plus radiotherapy
(CT ± RT) was used in eleven cases as the first line
treatment; 3 of these patients underwent adjuvant
radiotherapy. Seventeen cases underwent surgery
alone (OP) as a first line therapy, and 15 cases
underwent surgery plus chemotherapy (OP +
CT).
Chemotherapy regimens used in the study are
summarized in Table 2. A majority of the patients
received the CHOP regimen with or without
Rituximab. In those treated by OP, one case had
a total gastrectomy, and 16 cases had a subtotal
gastrectomy. In those treated by OP + CT, 11
cases had a total gastrectomy, and 4 had a
subtotal gastrectomy. One case in those treated
by OP + CT underwent an emergency operation
due to panperitonitis from perforation; the rest in
this group underwent surgery with curative
intent.
Response to treatment
The results of each treatment modality are
shown in the Table 3 and Fig. 1 and 2. Within the
first 3 - 6 cycles of chemotherapy, seven patients
treated by CT ± RT completely responded, and 3
partially responded (complete response rate,
63.6%; overall response rate, 90.9%). One partial
responder achieved complete response after the
second line chemotherapy. The other two partial
responders refused further treatment but remained
alive at the conclusion of this study. One patient
discontinued treatment after only 1 cycle of
chemotherapy and died 1 year after chemotherapy.
The complete response and overall response rates
were both 100% in those treated by OP and in
those treated by OP + CT. One patient treated by
CT ± RT relapsed, as did 4 patients treated by OP
and 1 patient treated by OP + CT. One patient
(9.1%) treated by CT ± RT died, as did 3 (17.6%)
treated by OP and 1 (6.7%) treated by OP + CT.
In all, there were a total of 5 (11.6%) deaths, and
Table 2. Chemotherapy Regimens
Tx group Regimen No.
CT ± RT R-CHOP 4
CHOP 3
ProMACE/CytaBOM 2
OP + CT CHOP 5
R-CHOP 1
CHOP + Etoposide 1
CEOP 1
BACOP 2
VACOP 3
BACOP + ProMACE/CytaBOM 1
R-VACOP 1
CHOP, Cyclophosphamide 750 mg/m2 at D1, doxorubicin 50 mg/m2 at D1, vincristine 1.4 mg/m2 at D1, prednisolone 100 mg
at D1 to D5; R-CHOP, Rituximab 375 mg/m
2
at D1, added to CHOP; ProMACE/CytaBOM, Prednisolone 60 mg/m
2
at D1 to
D14, doxorubicin 25 mg/m
2
at D1, cyclophosphamide, etoposide 120 mg/m
2
at D1, cytarabine 300 mg/m
2
at D8, bleomycin 5
U/m
2
at D8, vincristine 1.4 mg/m
2
at D8, methotrexate 120 mg/m
2
at D8, leucovorin 25 mg/m
2
by P.O. 6 times per day on
methotrexate administration; BACOP, Bleomycin 5 U/m2 at D15 & D12, doxorubicin 25 mg/m2 at D1 & D8, cyclophosphamide
650 mg/m
2
at D1 & D8, vincristine 1.4 mg/m
2
at D1 & D8, prednisolone 60 mg/m
2
on D1 to D14; CAVOP, Cyclophosphamide
550 mg/m
2
on D1, doxorubicin 35 mg/m
2
on D1, etoposide 100 mg/m
2
on D1, vincristine 1.2 mg/m
2
on D1, prednisolone 50
mg/m
2
on D1 to D10; R-CAVOP, Rituximab 375 mg/m
2
on D1 added to CAVOP.
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all died as a result of disease progression.
The overall survival rate for all 43 cases was
91.4% at both the 3- and 5-year time points.
Disease free survival was 100% at 3 years and
93.8% at 5 years. The 3-year overall survival rate
of those treated by CT ± RT was 85.7%. It was
87.5% for those treated by OP and 100% for those
treated by OP + CT. The 5-year overall survival
rate was the same as the 3-year overall survival
rate in all groups (p = 0.76). The 3-year disease
free survival rate was 100% in those treated by CT
± RT and by OP + CT, and it was 87.5% in those
treated by OP. The 5-year disease free survival
rate was 100% in those treated by CT ± RT, 77.8%
in those treated by OP, and 100% in those treated
by OP + CT (p = 0.99).
Complications
Table 4 lists complications that arose in each
group. Two cases experienced sepsis during the
neutropenic period but fully recovered with anti-
biotics and G-CSF (Granulocyte-Colony Stimu-
lating Factor). One case treated by CT had upper
gastrointestinal bleeding during chemotherapy
and was successfully treated by endoscopy. Two
cases treated by OP suffered malabsorption after
gastrectomy, and 1 case presented with frequent
reflux of bile. Among those treated by OP + CT,
2 cases had malabsorption, and 1 case had
Table 3. Complete Response, Overall Survival, and Disease Free Survival in Patients with Different Treatment
Modalities
No.
CR
(%)
RR
(%)
Relapse
(n)
Death
(n)
OS (%)
p
DFS s (%)
p
3-year 5-year 3-year 5-year
Total 43 93.0 97.7 5 5 91.4 91.4 100 93.8
CT ± RT 11 63.6 90.9 1 1 89.0 85.7 100 100
OP 17 100 100 4 3 87.5 87.5 0.76 87.5 77.8 0.99
OP + CT 15 100 100 1 1 100 100 100 100
CR, complete response; RR, response rate; OS, overall survival; DFS, disease-free survival; CT ± RT, chemotherapy group and
chemotherapy followed by radiotherapy group; OP, surgery alone group; OP + CT, surgery followed by chemotherapy group.
Fig. 1. Overall survival. Fig. 2. Disease free survival.
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panperitonitis due to cancer perforation before
diagnosis. Among the 4 cases treated by OP and
the 6 cases treated by OP + CT who underwent
gastrectomy and who had regular follow-ups to
measure serum vitamin B12 and folic acid levels,
there was found none of them (4 cases total
gastrectomy, 6 cases subtotal gastrectomy).
DISCUSSION
Studies have long supported surgery as the first
line of treatment for patients with localized gastric
lymphoma.6,7 The rationale for surgery as a
first-line treatment included the fact that patients
who underwent surgery had a better prognosis
than those who did not. Also, surgery might
reduce the chance of perforation or gastroin-
testinal bleeding during chemotherapy. Finally,
surgery allowed exact staging of patients. Maor et
al. reviewed 79 cases of primary gastric non-
Hodgkin’s lymphoma (stages IE and IIE) and
compared the survivors in each treatment group.
Even though there were few cases, their data
suggested a reassessment of surgery as the first-
line treatment. Laparotomy and resection asso-
ciated with substantial mortality and morbidity,
and accurate staging by laparotomy seldom
changed treatment. Specifically, there were 5
perioperative deaths among 31 patients (16%)
who underwent surgery, while there were no
complications among the 35 patients treated by
chemotherapy. CHOP-Bleo (cyclophosphamide,
vincristine, doxorubicin, prednisolone, bleomycin)
chemotherapy alternated with local radiotherapy
can achieve local tumor control and obviates the
need for resection. Thus, Maor et al. recom-
mended that surgical resection be reserved for
tumors that do not respond to initial chemo-
therapy or for cases with complications.8
According to Avilés et al., 28 cases were treated
with a regimen of CHOP-Bleo alternating with
CMED (cyclo-phosphamide, methotrexate, etopo-
side and dexamethasone), and 24 cases received
the same regimen after surgery. The complete
remission rate for chemotherapy was 92.9% (26
cases). There was no significant difference
between the two groups.9
Liu et al. advocated systemic chemotherapy
alone after comparing the treatment outcome of
surgery plus chemotherapy (21 cases) versus
chemotherapy alone (38 cases) for early gastric
diffuse large-cell lymphoma. The complete
response rate in those treated by chemotherapy
was 80.6%, and the overall response rate was
83.3%. The 5-year overall survival rate and
relapse-free survival rate were 72.6% and 86.0%,
respectively, in those treated by chemotherapy
alone, while they were 77.8% and 77.9%,
respectively, in those treated by surgery plus
chemotherapy (p = 0.40, overall survival; p = 0.94,
relapse-free survival).10
Avilés et al. conducted another controlled
clinical trial for 589 cases of primary early stage
diffuse large cell gastric lymphoma. In their
study, 10-year overall survival rates were 54% for
surgery, 53% for surgery plus radiotherapy, 91%
for surgery plus chemotherapy, and 96% for
chemotherapy (p < 0.001). Event-free survival
rates at 10 years were 27% for surgery, 23% for
surgery plus radiotherapy, 82% for surgery plus
chemotherapy, and 92% for chemotherapy.11
Treatments that included chemotherapy resulted
in better survival than surgery.
Table 4. Complications of Treatment
Treatment Complication No.
CT ± RT Sepsis due to neutropenia 2
Upper gastrointestinal bleeding 1
OP Malabsorption 2
Bile regurgitation 1
OP + CT Malabsorption 2
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Furthermore, in another Korean multi-center
study, Kang et al. reviewed 130 cases of primary
aggressive B-cell lymphoma of the stomach.
Complete response rates were 80% for chemo-
therapy. Three-year failure-free survival rates
were 78% for chemotherapy and 84% for surgery
plus chemotherapy (p = 0.1735). Three-year overall
survival rates were 86% for chemotherapy and
88% for surgery plus chemotherapy (p = 0.441).
Our data and the abovementioned reports strongly
suggest that surgery gives no additional advantage
to the survival and prevention of relapse.12
In a recent randomized multi-center study
supporting stomach-preserving treatment for
gastric lymphoma,13 the overall survival rate was
86.6% for surgical management and 87.0% for
stomach-preservation 42 months after treatment.
The event-free survival rates were 83.9% for
surgical management and 84.5% for stomach
preservation, which is not significantly different.
Due to treatments for complications, perio-
perative mortality was 1.5 - 16%.8,14 However,
Gobbi et al reviewed 682 cases and redefined
perioperative mortality as 7.2% (49 cases).15 Anas-
tomosis leakage was observed in 1.5 - 5% of the
cases,10,14 and gastrointestinal bleeding from the
remnant stomach or from the anastomosis site
was observed in 1.5 - 10% of the cases.10,14 The
most common late post-surgical complications
were 'dumping syndrome' (6.4%) and malabsor-
ption (5.5%).11 In contrast to those treated by
surgery, the most common complication following
chemotherapy was neutropenia (8.5 - 71%),
accompanied by sepsis in 5.6% of the cases.
16,17
Gastrointestinal bleeding was reported in 3 - 5.6%
of the cases,10,16 and perforation occurred in 5% of
the cases.10 In Gobbi’s report, 5 of 188 patients
(2.7%), who underwent stomach-preservation
treatment, died of gastrointestinal bleeding or
perforation.
15
In the current study, there was no perioperative
or chemotherapy-related mortality, markedly
different from previously reported studies. In
contrast to Gobbi’s report of chemotherapy-
related fatal complications, such as gastroin-
testinal bleeding and perforation, we observed no
perforations and only 1 case (9%) of bleeding,
which was successfully controlled. Neutropenia
and sepsis were observed more frequently here
than in other Korean studies. Surgery-related
malabsorption was observed here more frequently
than in Aviles’ study, whereas anastomosis
leakage and bleeding were not seen here.
Total gastrectomy removes IF-producing cells
and leads to cobalamin deficiency in about 5 years
(range, 2 - 10 years). After subtotal gastrectomy,
less than 1% of patients show frank cobalamin
deficiency, but 25 - 50% have depressed cobalamin
levels.18 The importance of cobalamin deficiency
from gastrectomy has been emphasized because
of occasional non-reversible neurological deficits.
In a Korean report of 59 cases with total gastrec-
tomy, 41 cases (69.5%) developed B12 deficiency 4
years after surgery. Neurologic deficit occurred in
9 cases (15.3%) in a median time of 33.4 months.19
Hines et al. and Khalid et al. reported cobalamin
deficiency in only 10 - 20% of patients 8 years
after partial gastrectomy. Up to 6% of these
cobalamin-deficient patients developed manifesta-
tions of cobalamin deficiency with megaloblastic
anemia.20,21 In our study, 4 cases who were treated
by total gastrectomy and 6 cases treated by
subtotal gastrectomy were followed up for longer
than 5 years (maximal 9.6 years follow up for total
gastrectomy, 7.5 years for subtotal gastrectomy).
There was no reported occurrence of vitamin B12
deficiency or megaloblastic anemia in our study,
which inevitably arises from total or subtotal
gastrectomy.
In conclusion, to prevent morbidities arising
from early or late surgical complication and to
promote quality of life, chemotherapy should be
considered a primary choice in early stage diffuse
large B-cell lymphoma of the stomach. Also,
further studies are needed to determine whether
the best chemotherapy regimen involves radiation.
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